[HTML][HTML] SARS-CoV-2 variants, immune escape, and countermeasures
Y Zhang, H Zhang, W Zhang - Frontiers of medicine, 2022 - Springer
Abstract Coronavirus disease 2019 (COVID-19) has become a global pandemic disease.
SARS-CoV-2 variants have aroused great concern and are expected to continue spreading …
SARS-CoV-2 variants have aroused great concern and are expected to continue spreading …
[HTML][HTML] The success of SARS-CoV-2 vaccines and challenges ahead
K Subbarao - Cell host & microbe, 2021 - cell.com
The rapid and remarkably successful development, manufacture, and deployment of several
effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines is now …
effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines is now …
[HTML][HTML] Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2
The emerging SARS-CoV-2 variants of concern (VOCs) threaten the effectiveness of current
COVID-19 vaccines administered intramuscularly and designed to only target the spike …
COVID-19 vaccines administered intramuscularly and designed to only target the spike …
[HTML][HTML] Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection
Background Assessment of the kinetics of SARS-CoV-2 antibodies is essential in predicting
risk of reinfection and durability of vaccine protection. Methods This is a prospective …
risk of reinfection and durability of vaccine protection. Methods This is a prospective …
SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma
E Andreano, G Piccini, D Licastro… - Proceedings of the …, 2021 - National Acad Sciences
To investigate the evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) in the immune population, we coincupi bated the authentic virus with a highly neutralizing …
2) in the immune population, we coincupi bated the authentic virus with a highly neutralizing …
Reduced sensitivity of infectious SARS-CoV-2 variant B. 1.617. 2 to monoclonal antibodies and sera from convalescent and vaccinated individuals
D Planas, D Veyer, A Baidaliuk, I Staropoli… - Biorxiv, 2021 - biorxiv.org
Abstract The SARS-CoV-2 B. 1.617 lineage emerged in October 2020 in India–. It has since
then become dominant in some indian regions and further spread to many countries. The …
then become dominant in some indian regions and further spread to many countries. The …
[HTML][HTML] Host immunological responses facilitate development of SARS-CoV-2 mutations in patients receiving monoclonal antibody treatments
A Gupta, A Konnova, M Smet, M Berkell… - The Journal of …, 2023 - Am Soc Clin Investig
Background The role of host immunity in emergence of evasive SARS-CoV-2 Spike
mutations under therapeutic monoclonal antibody (mAb) pressure remains to be explored …
mutations under therapeutic monoclonal antibody (mAb) pressure remains to be explored …
[HTML][HTML] Highly specific memory B cells generation after the 2nd dose of BNT162b2 vaccine compensate for the decline of serum antibodies and absence of mucosal …
E Piano Mortari, C Russo, MR Vinci, S Terreri… - Cells, 2021 - mdpi.com
Specific memory B cells and antibodies are a reliable read-out of vaccine efficacy. We
analysed these biomarkers after one and two doses of BNT162b2 vaccine. The second dose …
analysed these biomarkers after one and two doses of BNT162b2 vaccine. The second dose …
Phytochemicals-based targeting RdRp and main protease of SARS-CoV-2 using docking and steered molecular dynamic simulation: A promising therapeutic …
The ongoing COVID-19 pandemic has affected millions of people worldwide and caused
substantial socio-economic losses. Few successful vaccine candidates have been approved …
substantial socio-economic losses. Few successful vaccine candidates have been approved …
[HTML][HTML] Molecular rationale for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and etesevimab monoclonal antibodies
The purpose of this work is to provide an in silico molecular rationale of the role eventually
played by currently circulating mutations in the receptor binding domain of the SARS-CoV-2 …
played by currently circulating mutations in the receptor binding domain of the SARS-CoV-2 …